STE

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Steris (STE) reported earnings 30 days ago. What's next for the stock?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

STERIS' Healthcare and AST segments post solid gains and milestones, but FX volatility, tariffs and global macro pressures threaten earnings variability.

STERIS NYSE: STE reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing gains, while also outlining expectations for mid- to high-single-digit growth in fiscal 2027.

STERIS posts Q4 adjusted EPS of $2.83 and revenues of $1.59 billion, both slight misses; shares dip after hours despite broad growth and FY27 guidance.

STERIS plc (STE) Q4 2026 Earnings Call Transcript

DUBLIN, IRELAND, May 11, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7% to $1.6 billion compared with $1.5 billion in the fourth quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations grew 5% in the fourth quarter.

DUBLIN, IRELAND, May 07, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that, effective May 5, 2026, Pierre Boulud has been appointed to the Board of Directors. “We are pleased to welcome Pierre to our Board,” said Mohsen Sohi, Chairman of STERIS.